MedTrace Logo

An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy

NCT07631871 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-06-08

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if Zanidatamab can treat HER2-positive advanced tumors in adults. The main question it aims to answer is: What is the objective response rate of Zanidatamab in adult patients with HER-2 positive advanced solid tumors? Participants will receive Zanidatamab intravenously on Day 1 of each 2-week treatment cycle. The dosage is 20 mg/kg per cycle.

Conditions

  • Neoplasms
  • Solid Tumors
  • HER2 Positive Solid Tumor
  • Endometrial Neoplasm
  • Urothelial Carcinoma (UC)
  • Pancreatic Neoplasms
  • Colorectal Neoplasms
  • Head and Neck Neoplasms
  • Cervical Neoplasms
  • Ovarian Neoplasms

Interventions

DRUG

Zanidatamab

Treatment continues until disease progression, intolerable toxicity, subject withdrawal or study termination.

Sponsors & Collaborators

  • Haihua Yuan

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-15
Primary Completion
2029-12-31
Completion
2029-12-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07631871 on ClinicalTrials.gov